论文部分内容阅读
急性呼吸道疾病(ARD)是美国进行基本战斗训练的新兵发病和住院最常见的原因,主要由腺病毒_4(ADV-4)和腺病毒(ADV-7)引起。1966年开始的腺病毒监测计划表明ADV-4疫苗安全,在减少因ADV-4感染的ARD方面是有效的,但对ADV-7所致的ARD基本无效,故降低ARD发病率有限。1970年制备ADV-7疫苗,可与ARD-4疫苗同时应用,为控制新兵ARD的一种有效方法。其成本效益分析是将发展疫苗、试验、购置及使用经费与疫苗接种所获效益进行比较。效益系计算疾病所需费用,包括直接费用与间接费用。直接费用为病人管理、药物和医疗供给费用;
Acute respiratory disease (ARD) is the most common cause of the onset and hospitalization of recruits in basic combat training in the United States. It is mainly caused by adenovirus 4 (ADV-4) and adenovirus (ADV-7). The adenovirus surveillance program that began in 1966 showed that the ADV-4 vaccine is safe and effective in reducing the ARDs associated with ADV-4 infection. However, the ARDs caused by ADV-7 are basically ineffective. Therefore, the reduction of ARD incidence is limited. The ADV-7 vaccine was prepared in 1970 and can be applied simultaneously with the ARD-4 vaccine, which is an effective method for controlling recruits’ ARD. Its cost-benefit analysis compares the development of vaccines, trials, acquisitions, and use funds with the benefits of vaccination. Benefits are the cost of calculating the disease, including direct and indirect costs. Direct costs for patient management, medication, and medical supply costs;